The global microbiome therapeutics market size valued USD 262.3 million in 2020 and expected to grow at a CAGR of 22.6% during the forecast period 2021-2027. A microbiome is genetic material of all microbes such as bacteria, virus, fungi, and protozoa that live on and inside the human body. Every part of the body has different types of microbes. For instance, about a third bacteria in the gut are Bacteroides species, whereas Streptococcus species are dominant about oral health. Microbiome Therapeutics Market plays a significant role in human health and disease conditions. Global Microbiome Therapeutics Market is still nascent stage, very products in the market are currently approved to treat various therapeutic conditions. Start-ups are very active in the microbiome therapeutics market in terms of product launches, research and development activities. However, bigger players in the microbiome therapeutics market are focused to provide funding, collaborating and acquiring smaller players to promote the research activities. Furthermore, Venture Capitalists and Government Organisations are actively involved in funding and encouraging research activities. The launch of microbiome therapeutics products in the market expected to fuel the demand of the market over the forecast. For instance, in May 2014, Pfizer entered an agreement with Second Genome to conduct research on obesity and metabolic disorders. In April 2016, the company also raised US$ 42.6 Mn in Series B funding led by Pfizer Venture Investments and Roche Venture Fund. The funding amount will be used to conduct the clinical investigation on SGM-109, a small molecule inhibitor of a microbiome mediated target to address inflammation and pain conditions in ulcerative colitis. In February 2016, Synlogic raised US$ 40 Mn in Series-B from OrbisMed Healthcare Fund Management to expand its research programs on inflammatory bowel disease conditions and to develop therapeutics for inborn errors of metabolism of Urea Cycle Disorder and Phenylketonuria conditions.